Loading stock data…
LEGN
$33.49+1.97 (+6.25%)
After Hours$33.49+0.00 (+0.00%)· Last close Jun 9
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Legend Biotech Corporation in the Healthcare sector is trading at $33.49. Wall Street consensus targets $57.59 (15 analysts), implying a +72.0% move over the next 12 months. The stock is currently 26% below its 52-week high of $45.30, remaining 30.1% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +72.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$33.49
Potential Downside
0%
Whystock Fair Value$33.49
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Buy
Mean target$57.59+72.0%
Range$27.00 – $86.00
Fundamentals
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-25.85%
Volume
Today's trading volume
1.82M
Recent News
Legend Biotech (LEGN) Is Up 26.2% After Early In Vivo CAR-T Success in B-Cell Lymphoma
In early June 2026, Legend Biotech reported early Phase 1 data for LB2501 in relapsed/refractory B-cell non-Hodgkin lymphoma, showing high response rates, durable in vivo CAR-T expansion without lymphodepletion, and a manageable safety profile in 12 treated patients. The LB2501 results introduce an in vivo, off-the-shelf CAR-T approach that removes complex cell manufacturing and preconditioning, potentially reshaping how B-cell malignancies are treated if future trials confirm these early...
Legend surges on early data for ‘in vivo’ lymphoma cell therapy
Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.
Legend Biotech (LEGN) Soars 42% on Promising Cancer Therapy Results
Legend Biotech Corp. (NASDAQ:LEGN) is one of the 10 Stocks Delivering Massive Returns. Legend Biotech snapped a four-day losing streak on Tuesday, jumping 42.22 percent to close at $36.28 apiece following the strong first phase results of its cancer treatment candidate, which saw as much as a 100 percent response rate in enrolled patients. In […]
Legend's Cancer-Fighter Notches Elusive 100% Success Rate; What's Next?
Legend Biotech said Tuesday all six patients in a Phase 1 study of its in vivo CAR-T responded to the lymphoma treatment.
Legend Stock Surges After Blood- Cancer Drug Shrinks Tumors in Study
Shares of Legend Biotech rose more than 40% Tuesday—on pace for the stock's biggest percentage increase on record—after the company said its experimental cancer treatment shrank tumors in all six patients who received the highest dose tested, including five who showed no detectable signs of cancer.